CSS
ONCT

Cubist Systematic Strategies’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Cubist Systematic Strategies’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-995
Closed -$28K – 4656
2022
Q1 		$28K Buy
+995
New +$36.2K ﹤0.01% 3451
2021
Q3 		– Sell
-1,015
Closed -$96K – 3249
2021
Q2 		$96K Sell
1,015
-926
-48% -$110K ﹤0.01% 2716
2021
Q1 		$323K Buy
+1,941
New +$257K ﹤0.01% 2210

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Cubist Systematic Strategies's ONCT Position: Q2 2022 in Review

Cubist Systematic Strategies sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 995 shares — an estimated $28K sold.

Cubist Systematic Strategies first reported a position in ONCT in Q1 2021 and held it in 3 quarters. The position peaked at $323K in Q1 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Cubist Systematic Strategies reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 995 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $28K.
  • Cubist Systematic Strategies first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Cubist Systematic Strategies's Oncternal Therapeutics, Inc. Common Stock position peaked at $323K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.